Open AccessSpecific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
Author(s) -
Aïda Falgàs,
Víctor Pallarès,
Ugutz Unzueta,
Yáiza Núñez,
Jorge Sierra,
Alberto Gallardo,
Lorena Alba-Castellón,
María Antònia Mangues,
Patricia Álamo,
Antonio Villaverde,
Esther Vázquez,
Ramón Mangues,
Isolda Casanova
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s289733
Subject(s) - cancer research , diffuse large b cell lymphoma , lymphoma , chemistry , medicine , pharmacology , pathology
Around 40-50% of diffuse large-B cell lymphoma (DLBCL) patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL patients involve microtubule targeting agents (MTAs), however, their anticancer activity is limited by severe side effects. Therefore, we chose to improve the therapeutic window of the MTA monomethyl auristatin E developing a nanoconjugate, T22-AUR, that selectively targets the CXCR4 receptor, which is overexpressed in many DLBCL cells (CXCR4 + ) and associated with poor prognosis.